Search Results
May 11, 2026, 09:42 ET Hengrui Pharma and Braveheart Bio Announce Positive Phase 2 Results with HRS/BHB-1893 in Non-Obstructive Hypertrophic Cardiomyopathy
double-blind, placebo-controlled Phase 2 study evaluating HRS-1893 (also known as BHB-1893), an investigational next-generation cardiac myosin inhibitor (CMI), in patients with non-obstructive hypertrophic cardiomyopathy (nHCM). HRS/BHB-1893 treatment resulted in improvements across biomarkers of cardiac wall
More news about: Braveheart Bio
Apr 10, 2026, 16:50 ET GOLDFISH SWIM SCHOOL'S FIRST FRANCHISE GROUP RECEIVES 2026 MVP AWARD FROM MULTI-UNIT FRANCHISEE MAGAZINE
BHB Group joined Goldfish Swim School in 2009 as the company's very first franchise group. Since then, the group has dedicated 17 years to building what is now a large multi-unit ownership group in the Goldfish Swim School system, with 33 schools in nine states. BHB Group is led by Katie
More news about: Goldfish Swim School
Mar 30, 2026, 09:35 ET Hengrui Pharma and Braveheart Bio Announce Positive Phase 2 Results with HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy
NCT06516068) of 42 patients was designed to measure efficacy and safety of BHB/HRS-1893 and to evaluate dose regimen options that could shorten the time to an effective dose. Patients were randomized 1:1:1 to receive oral BHB/HRS-1893 20 mg twice daily (potentially titrated up to 60 mg; Group 1), 40
More news about: Braveheart Bio
Mar 26, 2026, 08:00 ET Braveheart Bio Appoints Emil deGoma, M.D., as Chief Medical Officer
in the development of BHB-1893," said Emil deGoma, M.D. "The opportunity to help advance a potentially best-in-class therapy for patients living with hypertrophic cardiomyopathy is truly exciting. I look forward to collaborating with the talented team at Braveheart to advance BHB-1893 through global development."About
More news about: Braveheart Bio
Mar 26, 2026, 08:00 ET Impossible Foods Held Liable for Intentional and Malicious Infringement of "IMPOSSIBLE" Trademark Owned By Endurance Athlete and Influencer Joel Runyon -- Federal Jury Awards Compensatory and Punitive Damages
SAN JOSE, Calif., March 26, 2026 /PRNewswire/ -- On March 24, 2026, BraunHagey & Borden's ("BHB") trial team—led by Adam Cashman and Marissa Benavides—secured a complete victory for clients Impossible LLC and Joel Runyon against meat-alternative
More news about: BraunHagey & Borden LLP
Feb 23, 2026, 08:00 ET Braveheart Bio to Participate in TD Cowen 46th Annual Health Care Conference
Horowitz (a16z Bio + Health), Forbion, OrbiMed, Enavate Sciences (a platform of Patient Square Capital) and Frazier Life Sciences. Braveheart is advancing BHB-1893 through late-stage clinical development with the goal of establishing a new standard of care. For more information, visit
More news about: Braveheart Bio
Feb 05, 2026, 08:00 ET Braveheart Bio Announces Senior Leadership Appointments to Strengthen Scientific and Operational Capabilities While Advancing Global Phase 3 Development
Braveheart Bio. "Marc has been instrumental in shaping our strategy and elucidating the clinical and mechanistic differentiation for our lead program, BHB-1893. In his new role as Chief Scientific Officer, Marc will assume expanded responsibilities in managing our growing team of highly experienced researchers
More news about: Braveheart Bio
Jan 06, 2026, 14:00 ET Tsubame BHB's ammonia synthesis facilities to INPEX's Kashiwazaki Hydrogen Park begins trial production
issues faced by humans in relation to food and the environment, and achieving a sustainable society."About Tsubame BHB Co., Ltd. Tsubame BHB is a deep tech company with a Vision of "Leveraging original technologies to resolve critical issues faced by humans in relation to
More news about: Tsubame BHB Co., Ltd.
Jan 06, 2026, 08:00 ET Braveheart Bio to Present at 44th Annual J.P. Morgan Healthcare Conference
Horowitz (a16z Bio + Health), Forbion, OrbiMed, Enavate Sciences (a platform of Patient Square Capital) and Frazier Life Sciences. Braveheart is advancing BHB-1893 through late-stage clinical development with the goal of establishing a new standard of care. For more information, visit
More news about: Braveheart Bio
Dec 22, 2025, 09:00 ET MorseLife Donates $1 Million to Breaking Healthcare Barriers for Hurricane Melissa Relief Efforts
underserved communities in Jamaica, following the devastating impacts of Hurricane Melissa in October 2025. Partnering with Breaking Healthcare Barriers (BHB), a South Florida-based nonprofit dedicated to expanding access to healthcare for Jamaica's underserved communities, MorseLife's contribution is helping
More news about: MorseLife
Nov 21, 2025, 08:00 ET Announcing the Winners of the 2025 SHN Architecture & Design Awards
participants for our clients to connect with.WTWH Healthcare creates a number of digital publications, including Behavioral Health Business (BHB), HME Business (HMEB), Home Health Care News (HHCN), Hospice News (HSPN), Mobility Management (MM), Senior Housing News (SHN) and Skilled Nursing News
More news about: WTWH Media
Nov 05, 2025, 06:00 ET Braveheart Bio Launches with $185M Series A Aiming to Transform Care of Hypertrophic Cardiomyopathy
oHCM in China. The Company plans to initiate global late-stage clinical development for BHB-1893 in 2026. Early data recently presented at the European Society of Cardiology Congress 2025 on BHB-1893 in oHCM demonstrated rapid and clinically meaningful reduction in left ventricular
More news about: Braveheart Bio
Oct 09, 2025, 10:52 ET BraunHagey & Borden LLP: Supreme Court Declines to Hear Coinbase's Bid to Block Public Injunction Case, Preserving Californians' Right to Seek Public Relief in Court
the U.S. Supreme Court declined to hear Coinbase's appeal of the important ruling top litigation boutique BraunHagey & Borden LLP (BHB) obtained in Kramer v. Coinbase, which affirmed the rights of Californians to pursue claims for public injunctive relief in court
More news about: BraunHagey & Borden LLP
Sep 09, 2025, 11:32 ET Elite Litigation Firm Increases NYC Footprint - BraunHagey & Borden Moves Into Newly Renovated Class A Office Space at 200 Madison Avenue
San Francisco, has grown organically since launching a full-scale office in Manhattan six years ago. BHB vacated its prior 8,500 square feet office space in Flatiron to accommodate a growing partner, associate and client base. It now boasts over 20 attorneys
More news about: BraunHagey & Borden LLP